A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

Condition studied

Psoriatic arthritis​​

Investigational medicinal product(s)

Eligibility

Primary endpoint

Number of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 16

Endpoint detail

Number of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 16, Number of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 16, Mean Change from Baseline in the Health Assessment of Questionnaire Disability Index (HAQ-DI) at Week 16, Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Discontinue Study Intervention Due to an AE